IDRA - イデラ・ファ―マシュ―ティカルズ （Idera Pharmaceuticals Inc.） イデラ・ファ―マシュ―ティカルズIDRAのチャート
IDRAの企業情報
| symbol | IDRA |
|---|---|
| 会社名 | Idera Pharmaceuticals Inc （イデラ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 イデラ・ファーマシューティカルズ（Idera Pharmaceuticals Inc.）は腫瘍学及び希少疾患の治療薬の発見・開発・商業化に焦点を当てた臨床段階のバイオ医薬企業である。同社はトール様受容体（TLR）ターゲティング技術および第3世代アンチセンス（3GA）技術を含む薬物候補を設計・開発するために、2つの創薬技術プラットフォームを利用する。TLR技術を使用して、同社は特定のTLRの活性を調節することによって作用する合成オリゴヌクレオチドに基づく薬物候補を設計する。3GA技術を用いて、病気を引き起こす遺伝子に関連するメッセンジャーリボ核酸（mRNA）をオフにする薬剤候補を開発する。同社の薬物候補には、IMO-8400、IMO-2125およびIMO-9200が含まれる。同社は、TLRアンタゴニストおよびアゴニストを、標的化TLRの活性を調節することによって作用させるように設計した。同社は病気を引き起こす遺伝子に関連するmRNAを消す3GA技術を開発する。 イデラ・ファ―マシュ―ティカルズは、臨床段階の米国バイオテクノロジ―企業。自己免疫疾患の治療のためと特定の遺伝的に定義されたフォ―ムのB細胞リンパ腫の治療製薬の開発に従事する。癌、感染症やアルツハイマ―病などの分野でTLR7、TLR8、およびTLR9作用薬を含むワクチンの製品を、研究・開発、商業化する。 Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. |
| 本社所在地 | 167 Sidney Street Cambridge MA 02139 USA |
| 代表者氏名 | James A. Geraghty ジェームズ・A.グラガッティ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 484-348-1600 |
| 設立年月日 | 32629 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.iderapharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/idra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -65.52800 |
| 終値（lastsale） | 8.71 |
| 時価総額（marketcap） | 236684259.63 |
| 時価総額 | 時価総額（百万ドル） 191.30390 |
| 売上高 | 売上高（百万ドル） 0.75500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 97.25790 |
| 当期純利益 | 当期純利益（百万ドル） -65.58200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Idera Pharmaceuticals Inc revenues decreased 26% to $418K. Net loss decreased 1% to $36.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 17% to $24.4M (expense) Interest income increase of 62% to $482K (income). |
IDRAのテクニカル分析
IDRAのニュース
Idera Pharma Earnings, Revenue Beat in Q3 By Investing.com 2022/11/15 03:22:00 Investing.com
Idera Pharma Earnings, Revenue Beat in Q3
Idera Pharmaceuticals GAAP EPS of -$0.06, revenue of $0.05M 2022/11/14 23:35:02 Seeking Alpha
Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/14 21:05:00 Wallstreet:Online
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better
Idera Pharma Acquires Rare Disease Player, Names New CEO 2022/09/29 13:52:50 Benzinga
Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com
Idera Pharmaceuticals completes acquisition of Aceragen 2022/09/28 20:29:07 Seeking Alpha
Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.
Idera Pharma Earnings, Revenue Beat in Q3 By Investing.com 2022/11/15 03:22:00 Investing.com
Idera Pharma Earnings, Revenue Beat in Q3
Idera Pharmaceuticals GAAP EPS of -$0.06, revenue of $0.05M 2022/11/14 23:35:02 Seeking Alpha
Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/14 21:05:00 Wallstreet:Online
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better
Idera Pharma Acquires Rare Disease Player, Names New CEO 2022/09/29 13:52:50 Benzinga
Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com
Idera Pharmaceuticals completes acquisition of Aceragen 2022/09/28 20:29:07 Seeking Alpha
Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.
Idera Pharmaceuticals GAAP EPS of -$0.08 (NASDAQ:IDRA) 2022/03/31 20:39:58 Seeking Alpha
Idera Pharmaceuticals press release (IDRA): Q4 GAAP EPS of -$0.08.The company''s cash position as of December 31, 2021 was $32.5 million
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 2022/03/31 20:15:00 GlobeNewswire
EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021.
Top RSI Trades for the day: Carnival Corporation & plc (NYSE:CCL), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) 2021/12/23 23:09:23 Stock Equity
Carnival Corporation & plc (NYSE:CCL) with the stream of -0.24% also noticed, India Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) encountered a rapid change of -0.57% in the last hour of Thursdays trading The post Top RSI Trades for the day: Carnival Corporation & plc (NYSE:CCL), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) appeared first on Stocks Equity .
Bright Trending Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Tellurian Inc. (AMEX:TELL) 2021/12/20 00:50:49 Stock Equity
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) with the stream of 1.49% also noticed, India Tellurian Inc. (AMEX:TELL) encountered a rapid change of 0.68% in the last hour of Fridays trading session. Idera The post Bright Trending Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Tellurian Inc. (AMEX:TELL) appeared first on Stocks Equity .
Beholding Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Galiano Gold Inc. (AMEX:GAU) 2021/12/16 00:05:31 Stock Equity
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) with the stream of -25.28% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of -1.61% in the last hour of Wednesdays trading session. The post Beholding Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .